MIRA INFORM REPORT
|
Report Date : |
18.05.2011 |
IDENTIFICATION DETAILS
|
Name : |
HOFON PHARMACEUTICAL CO., LTD. |
|
|
|
|
Registered Office : |
No. 181, Wuchang Road, Yuhang District, Hangzhou, Zhejiang Province, 310005 Pr |
|
|
|
|
Country : |
China |
|
|
|
|
Date of Incorporation : |
21.06.1996 |
|
|
|
|
Com. Reg. No.: |
330000000014937 |
|
|
|
|
Legal Form : |
One-Person Limited Liability Company |
|
|
|
|
Line of Business : |
R&D and wholesale of Chinese patent drug, chemical
medicine preparation, chemical raw materials, antibiotics, biochemical drugs,
biological products |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment
Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2010
|
Country Name |
Previous Rating (30.09.2010) |
Current Rating (31.12.2010) |
|
China |
a2 |
a2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company name & address
hofon pharmaceutical co., ltd.
no. 181, wuchang
road, yuhang district, hangzhou,
zhejiang PROVINCE,
310005 PR CHINA
TEL: 86 (0)
571-88900712/88900699 FAX: 86 (0)
571-88052408
EXECUTIVE SUMMARY
INCORPORATION DATE :
june 21, 1996
REGISTRATION NO. : 330000000014937
REGISTERED LEGAL
FORM : One-person Limited Liability Company
STAFF STRENGTH :
500
REGISTERED CAPITAL : CNY 100,000,000
BUSINESS LINE : r&d, tradE
TURNOVER :
N/A
EQUITIES :
N/A
PAYMENT :
AVERAGE
RECOMM. CREDIT RANGE : moderate amount
MARKET CONDITION : COMPETITIVE
FINANCIAL CONDITION : UNDETERMINED
OPERATIONAL TREND : STEADY
GENERAL REPUTATION : AVERAGE
EXCHANGE RATE :
CNY 6.50 = usd 1
Adopted abbreviations
ANS - amount not stated
NS - not stated
SC - subject company (the company inquired by you)
NA - not available
CNY - China Yuan Renminbi
SC was registered as a one-person limited liability company
at local Administration for Industry & Commerce (AIC - The official body of
issuing and renewing business license).
Company Status: One-person Limited Liability Company Single person LLC refers to a
limited liability company set up by only one natural person or legal person
as the single shareholder of it. The minimum registered capital
of Single person LLC is CNY100,000. The shareholder’s capital contributes,
as set out by the articles of associations should be a lump-sum payment in
full. One natural person can only
invest in and set up one limited liability company, which is not permitted
to invest in and set up a new Single person LLC. As to any one-person limited
liability company, the sole-investor nature of the natural person or legal
person shall be indicated in the registration documents of the company and
shall be indicated in the business license thereof as well. The regulation of Single person
LLC should be set up by the shareholder The regulation of Single person
LLC has no shareholder meeting.
SC’s registered business
scope includes R&D and wholesale of Chinese patent drug, chemical medicine
preparation, chemical raw materials, antibiotics, biochemical drugs, biological
products, selling pre-packaged foods, bulk foods, selling disinfection
supplies, daily necessities, cosmetics, medical devices, consultation service,
technical training, domestic trade and international trade, industrial
investment.
SC is mainly
engaged in R&D and wholesale of Chinese patent drug, chemical medicine
preparation, chemical raw materials, antibiotics, biochemical drugs, biological
products.
Mr. Liu Xiaobin is
chairman of SC at present.
SC is known to
have approx. 500 employees at present.
SC is
currently operating at the above stated address, and this address houses its
operating office and factory in the industrial zone of Hangzhou. Our checks
reveal that SC owns the total premise, but the gross area is unspecified.
SC is
not known to host web site of its own at present.
Changes of its registered information are as follows:
|
Date
of change |
Item |
Before the
change |
After the change |
|
2009 |
Company name |
Holley Industry
Group Co., Ltd. |
Hofon Pharmaceutical Co., Ltd. |
MAIN
SHAREHOLDERS:
Name %
of Shareholding
Holley Group Co., Ltd. 100
Established on September 28, 1970, Holley
group is a multi-industry corporation with Holley Group Co., Ltd. as the parent
company and pharmaceuticals as its core business. Holley has involved in
diversified businesses across pharmaceuticals, power metering instruments and
power automation system, wireless and wide-band telecommunication, electronic
materials, real estate, agriculture, petrochemical and mining, etc. Holley enjoys
a strong employee force over 10,000 people around the globe, and has
established an international presence with manufacturing bases and branches in
USA, France, Russia, Argentina, India, Thailand and the Philippines, and
representative offices in more than ten countries in Africa.
Tel: 86 0571-89300088
Fax: 86 0571-88052408
Web: http://www.holley.cn
E-mail: webadmin@holley.cn
Address: Holley Technology Park, No.181 Wuchang
Avenue, Yuhang District, Hangzhou City
l
Chairman:
Mr. Liu Xiaobin , ID# 330725197011135730, 41
years old with university education. He is currently responsible for the
overall management of SC.
Working Experience(s):
At present Working
in SC as chairman, and also working in Holley Group Co., Ltd. as vice CEO.
l
Board Members:
Wang Licheng ID#
330125196009064112
Wang Xiaopeng ID# 110102196804152394
He Qin ID# 210302196009021234
Lin Yu ID# 330802196405114429
Luo Hong ID# 330102196810181221
Tu Guoliang ID# 33052119761129021X
Zhao Shenggang ID# 36020319771016301X
SC is mainly
engaged in R&D and wholesale of Chinese patent drug, chemical medicine preparation,
chemical raw materials, antibiotics, biochemical drugs, biological products.
SC’s products
mainly include: Chinese patent drug, chemical medicine preparation, chemical
raw materials, antibiotics, and etc.
SC sources its materials 100% from domestic
market, mainly Zhejiang. SC sells 80% of its products in domestic market, and
20% to overseas market, mainly Southeast Asian market.
The buying terms of SC include Check, T/T and Credit of 30-60 days. The
payment terms of SC include T/T, L/C and Credit of 30-60 days.
SC is
known to have any subsidiary at present.
Overall payment appraisal :
( ) Excellent (
) Good (X) Average (
) Fair ( ) Poor
( ) Not yet determined
The appraisal serves as a reference to reveal SC's payments habits and
ability to pay. It is based on the 3
weighed factors: Trade payment
experience (through current enquiry with SC's suppliers), our delinquent
payment and our debt collection record concerning SC.
Trade payment experience : SC did not
provide any name of trade/service suppliers and we have no other sources to
conduct the enquiry at present.
Delinquent
payment record : None in our database.
Debt collection record : No overdue amount owed by SC was placed to
us for collection within the last 6 years.
SC declined to
release its bank details.
Investigations were made with the local Administration for Industry and
Commerce (the authority that issuing and renewing business license), however,
no financial records of SC was found.
SC’s management declined to release any financial information.
SC is considered medium-sized in its line with a development history of
15 years. Credit up to moderate amount may be considered.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.45.07 |
|
UK Pound |
1 |
Rs.63.57 |
|
Euro |
1 |
Rs.72.97 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this report.
The assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any risk
and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its
officials.